Authors: Aviraj Sanjay zure, Tushar ravsaheb shingade , Vinay Vilas patil , Abhishek Mallinath Sutar , Sonali Mahadev Patil , vaishnavi Deepak Pawar , Anita Rangrao Pujari
Abstract: Current advancements in the treatment of Parkinson’s disease (PD) are shifting from purely symptomatic management to a dual approach: refining the delivery of existing dopaminergic therapies and developing experimental disease-modifying and neurorestorative interventions. While levodopa remains the gold standard, its long-term use is complicated by motor fluctuations and dyskinesia, prompting the development of novel delivery systems like continuous subcutaneous infusions (e.g., Vyalev and Onapgo) and inhaled levodopa to provide steadier symptom control. Simultaneously, emerging therapies including stem cell transplantation (e.g., bemdaneprocel), gene therapy (e.g., AB-1005), and immunotherapy targeting -synuclein are advancing through late-stage clinical trials with the goal of replacing lost neurons or halting disease progression.
